These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19002405)

  • 1. Comparative effects of once-daily molsidomine in coronary patients from two distinct European ethnicities.
    Messin R; Dubois C; Famaey JP
    Adv Ther; 2008 Nov; 25(11):1200-14. PubMed ID: 19002405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of once- and twice-daily formulations of molsidomine in patients with stable angina pectoris: double-blind and open-label studies.
    Messin R; Cerreer-Bruhwyler F; Dubois C; Famaey JP; Géczy J
    Adv Ther; 2006; 23(1):107-30. PubMed ID: 16644612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative short-term effect of once-daily molsidomine on chronic angina in general practitioners' versus cardiologists' coronary patient populations.
    Messin R
    Adv Ther; 2014 Jan; 31(1):91-106. PubMed ID: 24307221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of molsidomine once-a-day in patients with stable angina pectoris.
    Messin R; Opolski G; Fenyvesi T; Carreer-Bruhwyler F; Dubois C; Famaey JP; Géczy J
    Int J Cardiol; 2005 Jan; 98(1):79-89. PubMed ID: 15676171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short- and long-term effects of molsidomine retard and molsidomine nonretard on exercise capacity and clinical status in patients with stable angina: a multicenter randomized double-blind crossover placebo-controlled trial.
    Messin R; Karpov Y; Baikova N; Bruhwyler J; Monseu MJ; Guns C; Géczy J
    J Cardiovasc Pharmacol; 1998 Feb; 31(2):271-6. PubMed ID: 9475269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability to 1-year treatment with once-daily molsidomine in patients with stable angina.
    Messin R; Bruhwyler J; Dubois C; Famaey JP; Géczy J
    Adv Ther; 2006; 23(4):601-14. PubMed ID: 17050502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and chronic effect of molsidomine extended release on exercise capacity in patients with stable angina, a double-blind cross-over clinical trial versus placebo.
    Messin R; Boxho G; De Smedt J; Buntinx IM
    J Cardiovasc Pharmacol; 1995 Apr; 25(4):558-63. PubMed ID: 7596123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot double-blind randomized placebo-controlled study of molsidomine 16 mg once-a-day in patients suffering from stable angina pectoris: correlation between efficacy and over time plasma concentrations.
    Messin R; Fenyvesi T; Carreer-Bruhwyler F; Crommen J; Chiap P; Hubert P; Dubois C; Famaey JP; Géczy J
    Eur J Clin Pharmacol; 2003 Jul; 59(3):227-32. PubMed ID: 12734607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, randomized, placebo-controlled study of molsidomine in patients with stable effort angina receiving beta-blocker therapy with atenolol.
    De Backer GG; Derese A
    Am Heart J; 1985 Mar; 109(3 Pt 2):678-81. PubMed ID: 3883735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Influence of combination therapy (isosorbide dinitrate and molsidomine) on the incidence of angina pectoris in patients with coronary heart disease].
    Ciopor M; Fischer A; Turina J; Hess OM
    Praxis (Bern 1994); 1997 Nov; 86(47):1849-53. PubMed ID: 9480502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molsidomine and isosorbide dinitrate: a comparative trial of tolerance in long-term intake by IHD patients with stable angina of effort].
    Alimova EV; Martsevich SIu; Kutishenko NP; Metelitsa VI
    Ter Arkh; 1997; 69(12):37-40. PubMed ID: 9503532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate (ISDN) during acute and short-term administration in stable angina pectoris.
    Wagner F; Gohlke-Bärwolf C; Trenk D; Jähnchen E; Roskamm H
    Eur Heart J; 1991 Sep; 12(9):994-9. PubMed ID: 1936012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No effect of highly dosed nitric oxide donor molsidomine on the angiographic restenosis rate after percutaneous coronary angioplasty: a randomized, placebo controlled, double-blind trial.
    Wöhrle J; Höher M; Nusser T; Hombach V; Kochs M
    Can J Cardiol; 2003 Apr; 19(5):495-500. PubMed ID: 12717484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical comparison of antiischemic efficacy of isosorbide dinitrate and molsidomine.
    Lehmann G; Reiniger G; Beyerle A; Schömig A
    J Cardiovasc Pharmacol; 1998 Jan; 31(1):25-30. PubMed ID: 9456273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of molsidomine on rheological parameters and the incidence of cardiovascular events].
    Wöhrle J; Nusser T; Hoffmeister A; Kestler HA; Grebe OC; Höher M; Hombach V; Koenig W; Kochs M
    Dtsch Med Wochenschr; 2003 Jun; 128(24):1333-7. PubMed ID: 12802741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New drug forms of molsidomine, Corvaton-forte and Corvaton-retard, and their antianginal efficacy in stenocardia patients].
    Kukushkin SK; Shamarin VM; Manoshkina EM; Berzak NV; Petrosian KIu
    Ter Arkh; 1996; 68(1):29-30. PubMed ID: 8644025
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: results of the MEDCOR trial.
    Barbato E; Herman A; Benit E; Janssens L; Lalmand J; Hoffer E; Chenu P; Guédès A; Missault L; Pirenne B; Cardinal F; Vercauteren S; Wijns W
    Atherosclerosis; 2015 Jun; 240(2):351-4. PubMed ID: 25875387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ergometric study of a new vasodilator agent in angina: molsidomine. Value of combination with beta-blockaders].
    Witchitz S; Kolsky H; Moisson P; Valette H
    Arch Mal Coeur Vaiss; 1981 Apr; 74(4):463-71. PubMed ID: 6112971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina.
    Van Hove C; Carreer-Bruhwyler F; Géczy J; Herman AG
    Atherosclerosis; 2005 Jun; 180(2):399-405. PubMed ID: 15910868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-term molsidomine treatment versus isosorbide dinitrate and placebo on exercise tolerance in stable angina.
    Romano M; de Caprio L; Meccariello P; Cuomo S; Baldini F; D'Ascia C; Steinberg G; Chiariello M
    Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):246-9. PubMed ID: 6430811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.